Girard Sharp LLP is investigating potential claims on behalf of Evoqua stockholders who received shares of Xylem, Inc. through the 2023 merger.
If you are a former Evoqua stockholder who received Xylem stock in the 2023 merger, please fill out our form or call (866) 981-4800 for a free consultation.
More About the Xylem Investigation
On August 9, 2023, Spruce Point Capital Management, an investment management firm, released a forensic review of Xylem that revealed “concerns about the accuracy of the Company’s cash liquidity given findings of two sets of financial statements and its ability to meet Wall Street’s aggressive financial expectations.” Spruce Point found that the merger “is predicated primarily on $140 million of cost savings synergies, and despite dangling a carrot of potential revenue synergies, Xylem has not offered any quantitative assessment of the opportunities.” Spruce Point is predicting a 35-40% downside risk for Xylem stock.
If you are a former Evoqua stockholder who received Xylem stock in the 2023 merger, fill out the form above to speak to a Girard Sharp attorney about your rights.
Our Commitment to Excellence
Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We serve on the Plaintiffs’ executive committee in the recent spoofing litigation against JPMorgan Chase that settled for $60 million, a favorable resolution that the district court preliminarily approved in December 2021. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.
